Asia-Pacific Journalists Visit Coreline Soft to Explore Medical AI Applications in Global Screening Infrastructure
Coreline Soft, a medical imaging AI company, announced that a delegation of international journalists participating in the 2026 Jefferson Fellowships, organized by the U.S.-based East-West Center, visited its headquarters on November 10 to learn about the company's medical AI technologies and global business activities.The visit was part of an international journalism exchange program examining…
On November 10, a group of international journalists affiliated with the 2026 Jefferson Fellowships, facilitated by the U.S.-based East-West Center, toured Coreline Soft's headquarters to gain insight into the company's medical AI technologies and global business operations. Representing prominent media outlets such as CNN, Australia's ABC, and the Philippines' Rappler, the 12 journalists engaged with Coreline Soft's leadership to learn about the company's advancements and international impact.
Ryoungwoo Jang, Coreline Soft's Clinical Research Lead, detailed the company's significant achievements in both domestic and international markets. CEO Jin Kook Kim and Director Jiwan Kwak, responsible for North American operations, fielded questions from the journalists regarding Coreline Soft's global strategies and applications of medical AI in clinical environments.
A central focus of the presentation was Coreline Soft's "One CT, Multi-Disease" strategy, exemplified by the AVIEW platform, which can analyze chest CT scans for multiple conditions including pulmonary nodules, emphysema, and coronary artery calcification. This technology is poised to enhance national lung cancer screening programs and routine clinical practices.
Germany's nationwide lung cancer screening program, integrated into the country's health insurance system in April, served as a case study for the integration of AI into national screening infrastructure. Coreline Soft provides AI analysis solutions, including AVIEW LCS Plus, and its AVIEW HUB platform facilitates seamless information exchange across screening institutions, streamlining the screening workflow from initial readings to final reporting.
By leveraging both AI-based image analysis and screening operations, Coreline Soft has secured contracts with 115 out of approximately 310 participating screening institutions in Germany, accounting for about 37% as of September. In the United States, the company is working on integrating with hospital Picture Archiving and Communication Systems (PACS) and developing multi-disease chest CT analysis capabilities.
In October, Coreline Soft obtained U.S. FDA 510(k) clearance for AVIEW Aorta Metrics, bringing its total number of FDA clearances to 13. The company is also exploring opportunistic screening to detect additional diseases using existing medical images and addressing regulatory differences and decision-making processes across various countries when AI-generated findings diverge from physicians' clinical judgments.
The exchange provided Coreline Soft with an opportunity to share its experiences in screening and clinical environments in Korea and around the world, while engaging Asia-Pacific journalists in discussions about the potential of chest CT analysis to advance early disease detection and foster a more preventive healthcare system.
Written by urgent.news from Korea IT Times's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
